The Association of Female Reproductive Factors with Glaucoma and Related Traits

Madjedi, Kian; Stuart, Kelsey V.; Chua, Sharon; Foster, Paul J.; Strouthidis, Nicholas G.; Luben, Robert; Warwick, Alasdair; Kang, Jae H.; Wiggs, Janey L.; Pasquale, Louis R.; Khawaja, Anthony P.

doi:10.1016/j.ogla.2022.06.003

Cited by 18 publications

(11 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Berry et al focused on the association between physical activity and rates of macular thinning; they examined data from 8862 eyes from the UKBB and reported significant positive associations between physical activity (data obtained through accelerometer) and the cross-sectional total macular thickness in POAG patients (beta = 0.8 μm/standard deviation) [ 20 ]. On the other hand, Madjedi et al from the Modifiable Risk Factors for Glaucoma Collaboration and the UKBB Eye and Vision Consortium examined the association between physical activity (data also obtained through accelerometer), glaucoma, and its related characteristics [ 21 ]. Contrary to expectations, the authors reported no association between time spent in physical activity or physical activity level and glaucoma status, no association between high levels of physical activity and IOP, and no association with macular retinal nerve fiber layer thickness, yet more time in moderate and vigorous physical activity was associated with a thicker macular ganglion cell-inner plexiform layer [ 21 ].…”

Section: Resultsmentioning

confidence: 99%

Availability of Physical Activity Tracking Data from Wearable Devices for Glaucoma Patients

Bhanvadia,

Meller,

Madjedi

et al. 2023

Information

View full text Add to dashboard Cite

Physical activity has been found to potentially modulate glaucoma risk, but the evidence remains inconclusive. The increasing use of wearable physical activity trackers may provide longitudinal and granular data suitable to address this issue, but little is known regarding the characteristics and availability of these data sources. We performed a scoping review and query of data sources on the availability of wearable physical activity data for glaucoma patients. Literature databases (PubMed and MEDLINE) were reviewed with search terms consisting of those related to physical activity trackers and those related to glaucoma, and we evaluated results at the intersection of these two groups. Biomedical databases were also reviewed, for which we completed database queries. We identified eight data sources containing physical activity tracking data for glaucoma, with two being large national databases (UK BioBank and All of Us) and six from individual journal articles providing participant-level information. The number of glaucoma patients with physical activity tracking data available, types of glaucoma-related data, fitness devices utilized, and diversity of participants varied across all sources. Overall, there were limited analyses of these data, suggesting the need for additional research to further investigate how physical activity may alter glaucoma risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Availability of Physical Activity Tracking Data from Wearable Devices for Glaucoma Patients

Bhanvadia,

Meller,

Madjedi

et al. 2023

Information

View full text Add to dashboard Cite

show abstract

“…Pathway enrichment analysis demonstrated that these 32 significantly altered metabolites primarily belonged to 16 pathways (Figure S12). Among the top altered pathways, steroid hormone biosynthesis appears to be the critical node to high-match PACG pathophysiological concepts 25,26 : it connects with androstenedione. The molecular formula of androstenedione is shown in Figure S13.…”

Section: Discussionmentioning

confidence: 99%

Metabolomics Identifies and Validates Serum Androstenedione as Novel Biomarker for Diagnosing Primary Angle Closure Glaucoma and Predicting the Visual Field Progression

Ren

Qiu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Primary angle closure glaucoma (PACG) is the leading cause of irreversible blindness worldwide, and no reliable, effective diagnostic, and predictive biomarkers are used in clinical routines. A growing body of evidence shows metabolic alterations in patients with glaucoma. we aimed to develop and validate potential metabolite biomarkers to diagnose and predict the visual field progression of PACG. Methods: Here, we used a 5-phases (discovery phase, validation phase 1, validation phase 2, supplementary phase, and cohort phase) multicenter (EENT hospital, Shanghai Xuhui central hospital), cross-sectional, prospective cohort study design to perform widely-targeted metabolomics and chemiluminescence immunoassay to determine candidate biomarkers. Five machine learning (random forest, support vector machine, lasso, K-Nearest neighbor, and Gaussian NB) approaches were used to identify an optimal algorithm. The discrimination ability was evaluated using the area under the receiver operating characteristic curve (AUC). Calibration was assessed by Hosmer-Lemeshow tests and calibration plots. Results: Studied serum samples were collected from 616 participants, and 1464 metabolites were identified. Machine learning algorithm determines that androstenedione exhibited excellent discrimination and acceptable calibration in discriminating PACG across the discovery phase (discovery set 1, areas under the receiver operating characteristic curve [AUC] =1.0 [95%CI, 1.00-1.00]; discovery set, AUC=0.85 [95%CI, 0.80-0.90]) and validation phases (internal validation, AUC=0.86 [95%CI, 0.81-0.91]; external validation, AUC=0.87 [95%CI, 0.80-0.95]). Androstenedione also exhibited a higher AUC (0.92-0.98) to discriminate the severity of PACG. In the supplemental phase, serum androstenedione levels were consistent with those in aqueous humor (r=0.82, P=0.038) and significantly (P=0.021) decreased after treatment. Further, cohort phase demonstrates that higher baseline androstenedione levels (hazard ratio=2.71 [95% CI: 1.199-6.104], P=0.017) were associated with faster visual field progression. Conclusion: Our study demonstrates serum androstenedione as a novel biomarker that can be used to diagnose PACG and predict visual field progression.

show abstract

“…The relationship between female reproductive factors and POAG risk has been investigated in several studies, [63][64][65][66][67][68][69] with no clear association found with age at menarche, parity, years of reproductive duration, and/or oral contraceptive use. 69 However, studies have shown a consistent association between younger age of menopause and increased risk of POAG on one hand, and between PMH use and decreased POAG risk on the other, thus suggesting the importance of female sex hormones. 69 Specifically, the Rotterdam study included 3078 women and was the first to show an increased risk of POAG (OR: 2.6; 95% CI: 1.5-4.8) during early menopause (< 45 y).…”

Section: Female Sex Hormonesmentioning

confidence: 99%

“…69 However, studies have shown a consistent association between younger age of menopause and increased risk of POAG on one hand, and between PMH use and decreased POAG risk on the other, thus suggesting the importance of female sex hormones. 69 Specifically, the Rotterdam study included 3078 women and was the first to show an increased risk of POAG (OR: 2.6; 95% CI: 1.5-4.8) during early menopause (< 45 y). 63 Similarly, the Nurses' Health Study, a 22-year longitudinal cohort study with 66,417 female participants, found a decreased POAG risk in women older than 65 years of age with late menopause ( ≥ 54 y) [multivariable rate ratios (MVRRs): 0.53; 95% CI: 0.32-0.89].…”

Section: Female Sex Hormonesmentioning

confidence: 99%

Lessons From The Glaucoma Foundation Think Tank 2023: A Patient-Centric Approach to Glaucoma

Harris,

Verticchio Vercellin,

Weinreb

et al. 2023

Journal of Glaucoma

Self Cite

View full text Add to dashboard Cite

Purpose: To summarize the main topics discussed during the 28th Annual Glaucoma Foundation Think Tank Meeting “A Patient-Centric Approach to Glaucoma” held in New York on June 9th and 10th 2023. Methods: The highlights of the sessions on BIG DATA, genetics, modifiable lifestyle risk factors, female sex hormones, and neuroprotection in the field of primary open-angle glaucoma (POAG) were summarized. Results: The researchers discussed the importance of BIG DATA repositories available at national and international levels for POAG research, including the United Kingdom Biobank. Combining genotyped large cohorts worldwide, facilitated by artificial intelligence (AI) and machine learning approaches, led to the milestone discovery of 312 genome-wide significant disease loci for POAG. While these loci could be combined into a polygenic risk score with clinical utility, Think Tank meeting participants also provided analytical epidemiological evidence that behavioral risk factors modify POAG polygenetic risk, citing specific examples related to caffeine and alcohol use. The impact of female sex hormones on POAG pathophysiology was discussed, as was neuroprotection and the potential use of AI to help mitigate specific challenges faced in clinical trials and speed approval of neuroprotective agents. Conclusion: The experts agreed on the importance of genetics in defining individual POAG risk and highlighted the additional crucial role of lifestyle, gender, blood pressure, and vascular risk factors. The main takeaways also included that BIG DATA repositories and AI are important combinatory tools to foster novel strategies to prevent and stabilize glaucoma and, in the future, recover vision loss from the disease.

show abstract

The Association of Female Reproductive Factors with Glaucoma and Related Traits

Cited by 18 publications

References 69 publications

Availability of Physical Activity Tracking Data from Wearable Devices for Glaucoma Patients

Availability of Physical Activity Tracking Data from Wearable Devices for Glaucoma Patients

Metabolomics Identifies and Validates Serum Androstenedione as Novel Biomarker for Diagnosing Primary Angle Closure Glaucoma and Predicting the Visual Field Progression

Lessons From The Glaucoma Foundation Think Tank 2023: A Patient-Centric Approach to Glaucoma

Contact Info

Product

Resources

About